Interobserver concordance in implementing the 2010 ASCO/CAP recommendations for reporting er in breast carcinomas: A demonstration of the difficulties of consistently reporting low levels of er expression by manual quantification

American Journal of Clinical Pathology

Volumn 140, Issue 4, 2013, Pages 487-494

  Reisenbichler, Emily S ^a   Lester, Susan C ^a   Richardson, Andrea L ^a   Dillon, Deborah A ^a   Ly, Amy ^b   Brock, Jane E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Breast carcinoma; Concordance; Estrogen receptor; Immunohistochemistry

Indexed keywords

ANTIBODY; ER 1D5 ANTIBODY; ER SP1 ANTIBODY; ESTROGEN RECEPTOR; UNCLASSIFIED DRUG;

ALLRED SCORE; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; H SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCORING SYSTEM;

BREAST CARCINOMA; CONCORDANCE; ESTROGEN RECEPTOR; IMMUNOHISTOCHEMISTRY;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLINICAL LABORATORY TECHNIQUES; FEMALE; GUIDELINE ADHERENCE; HUMANS; OBSERVER VARIATION; PRACTICE GUIDELINES AS TOPIC; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SOCIETIES, MEDICAL; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84884958436     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP1RF9FUIZRDPI     Document Type: Article

References (20)

1. McGuire W, Carbone PP, Vollmer EP, eds. Estrogen Receptors in Human Breast Cancer. New York, NY: Raven Press; 1975.
2. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligandbinding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481. (Pubitemid 29220854)
3. Barnes DM, Harris WH, Smith P, et al. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer. 1996;74:1445-1451. (Pubitemid 26370738)
4. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-168. (Pubitemid 28144151)
5. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134:e48-e72.
6. Raghav KP, Hernandez-Aya LF, Lei X, et al. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer. 2012;118:1498-1506.
7. Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer. 2000;89:111-117. (Pubitemid 30185917)
8. Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen Alone or in Combination trial. J Clin Oncol. 2008;26:1059-1065.
9. Dowsett M, Salter J, Zabaglo L, et al. Predictive algorithms for adjuvant therapy: TransATAC. Steroids. 2011;76:777- 780.
10. Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol. 2005;123:16-20. (Pubitemid 40066167)
11. Morgan DA, Refalo NA, Cheung KL. Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy. Breast. 2011;20:215-219.
12. Cheang MC, Treaba DO, Speers CH, et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol. 2006;24:5637-5644. (Pubitemid 46631303)
13. Brock JE, Hornick JL, Richardson AL, et al. A comparison of estrogen receptor SP1 and 1D5 monoclonal antibodies in routine clinical use reveals similar staining results. Am J Clin Pathol. 2009;132:396-401.
14. Collins LC, Connolly JL, Page DL, et al. Diagnostic agreement in the evaluation of image-guided breast core needle biopsies: results from a randomized clinical trial. Am J Surg Pathol. 2004;28:126-131. (Pubitemid 38031631)
15. Diaz LK, Sahin A, Sneige N. Interobserver agreement for estrogen receptor immunohistochemical analysis in breast cancer: a comparison of manual and computer-assisted scoring methods. Ann Diagn Pathol. 2004;8:23-27. (Pubitemid 38199175)
16. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005;123:21-27. (Pubitemid 40066168)
17. Yamashita H, Yando Y, Nishio M, et al. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer. 2006;13:74-83.
18. Barton S, Zabaglo L, A'Hern R, et al. Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. Br J Cancer. 2012;106:1760-1765.
19. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011;29:4273-4278.
20. Gokhale S, Rosen D, Sneige N, et al. Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl Immunohistochem Mol Morphol. 2007;15:451-455. (Pubitemid 350307853)